We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Spironolactone improves endothelial dysfunction in ankylosing spondylitis.
- Authors
Syngle, Ashit; Vohra, Kanchan; Khichi, Dinesh; Garg, Nidhi; Verma, Inderjeet; Kaur, Ladbans
- Abstract
Chronic inflammation in ankylosing spondylitis (AS) is associated with vascular endothelial dysfunction which leads to accelerated atherosclerosis. Accelerated atherosclerosis contributes to premature cardiovascular disease and increased cardiovascular mortality in AS. Spironolactone inhibits the production of proinflammatory cytokines and improves endothelial dysfunction in rheumatoid arthritis. This study aimed to determine the effect of spironolactone in antitumor necrosis factor (TNF)-naive AS patients. Twenty anti-TNF-naive AS patients (M/F = 15/5) with high disease activity (Bath ankylosing spondylitis disease activity index, BASDAI >4) despite treatment with stable doses of conventional disease-modifying antirheumatic drugs were investigated. Inflammatory disease activity (BASDAI and Bath ankylosing spondylitis functional index (BASFI) scores, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels), serum nitrite concentration, and endothelium-dependent and -independent vasodilatation of the brachial artery were measured at baseline and after 12 weeks of therapy with oral spironolactone 2 mg/kg/day. Ten healthy subjects matched for age and sex acted as the control. Flow-mediated dilation (FMD) in AS patients at baseline was significantly impaired compared with healthy control group ( p < 0.001). After treatment, FMD improved from 11.3 ± 1.70 to 24.69 ± 2.34 % ( p < 0.001); nitrite concentration reduced from 7.9 ± 0.28 to 4.79 ± 0.19 μmol/L ( p < 0.001); ESR from 33.8 ± 4.38 to 15.13 ± 1.30 mm in the first hour, ( p < 0.001); and CRP level from 22.39 ± 3.80 to 6.3 ± 1.29 mg/dL, ( p < 0.001). BASDAI and BASFI also reduced significantly ( p < 0.001). The study suggests that in AS endothelial dysfunction is a part of the disease process. This is the first study to show that treatment with spironolactone improves both endothelial dysfunction and inflammatory disease activity in AS.
- Subjects
SPIRONOLACTONE; ANKYLOSING spondylitis; ENDOTHELIAL cells; INFLAMMATION; CARDIOVASCULAR disease related mortality; ATHEROSCLEROSIS; VASCULAR endothelium; PATIENTS
- Publication
Clinical Rheumatology, 2013, Vol 32, Issue 7, p1029
- ISSN
0770-3198
- Publication type
Article
- DOI
10.1007/s10067-013-2233-3